The FDA has approved Bevyxxa (betrixaban) for the prophylaxis of venous thromboembolism (VTE) in adult patients. The drug is manufactured by Portola Pharmaceuticals, Inc. (San Francisco, CA).
Indications: Bevyxxa (betrixaban) is approved for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted morbidity and other risk factors for VTE.
Dosage/administration: Recommended dose is an initial dose of 160 mg, followed by 80 mg once daily, taken at the same time each day with food. The recommended duration of treatment is 35 to 42 days.
Adverse reactions: The most common adverse reaction (>5%) is bleeding.
US Food and Drug Administration. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. FDA Web site. Updated June 23, 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564422.htm. Accessed June 29, 2017.
This Week's Must Reads
Total & CV Mortality After LDL-C Lowering, JAMA; 2018 Apr 17; Navarese, et al
PCSK9 Inhibitors for Tx of Hypercholesterolemia, Ann Pharmacother; ePub 2018 Apr 1; Patel, et al
High-Intensity Statin Use and LDL-C Control, J Clin Lipidol; ePub 2018 Apr 26; Lamprecht Jr, et al
Improving Adherence with ASCVD Interventions, Clin Cardiol; ePub 2018 Apr 17; Fentanes, et al
Lipid Screening in Children with NAFLD, J Pediatr; ePub 2018 Apr 13; Harlow, et al
Must Reads in FDA Actions
FDA Approves Giapreza for Treatment of Low BP, FDA news release; ePub 2017 Dec 21
FDA Approves EKG Device for Apple Watch, AliveCor news release; 2017 Nov 30
FDA Approves Expanded Indication for Tekturna, Noden Pharma news release; 2017 Nov 14
FDA Approves Xarelto for Extended Treatment of VTE, Bayer news release; ePub 2017 Oct 30
HeartWare HVAD System OK’d for Destination Therapy, Medtronic news release; 2017 Sep 27